ADEF
TVRD

Adams Diversified Equity Fund’s Tvardi Therapeutics TVRD Stock Holding History

Adams Diversified Equity Fund’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-639
Closed -$299K – 246
2018
Q4 		$299K Buy
639
+164
+35% +$106K 0.02% 210
2018
Q3 		$410K Buy
+475
New +$343K 0.02% 207

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adams Diversified Equity Fund's TVRD Position: Q1 2019 in Review

Adams Diversified Equity Fund sold out of Tvardi Therapeutics (TVRD) in Q1 2019, closing a stake of 639 shares — an estimated $299K sold.

Adams Diversified Equity Fund first reported a position in TVRD in Q3 2018 and held it in 2 quarters. The position peaked at $410K in Q3 2018. 135 funds tracked by Wall St. Rank hold TVRD as of Q1 2019.

  • Adams Diversified Equity Fund reported no remaining Tvardi Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Adams Diversified Equity Fund sold 639 Tvardi Therapeutics shares in Q1 2019, an estimated $299K.
  • Adams Diversified Equity Fund first reported a position in Tvardi Therapeutics in Q3 2018 and held it in 2 quarters.
  • Adams Diversified Equity Fund's Tvardi Therapeutics position peaked at $410K in Q3 2018.
  • 135 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2019.

Based on Adams Diversified Equity Fund's 13F filing for Q1 2019, filed 26 Apr 2019.